Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.292 SEK | -2.18% | -9.32% | -97.08% |
22/05 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
16/05 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.08% | 4.36Cr | |
+46.03% | 5.57TCr | |
-7.53% | 3.9TCr | |
+36.64% | 3.88TCr | |
-9.38% | 2.73TCr | |
+12.31% | 2.63TCr | |
-16.38% | 2.02TCr | |
+30.79% | 1.28TCr | |
+28.57% | 1.22TCr | |
-0.36% | 1.21TCr |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma AB Approves Election of Anders Tullgren as New Director of the Board and as Chairman of the Board